Jason Luke

Jason Luke at UPMC is a leading investigator in innate immune activation strategies to overcome immune exclusion in cancer, with particular expertise in STING (stimulator of interferon genes) agonists. His research has evaluated intratumoral and systemic STING agonists to trigger innate immune signaling that can recruit adaptive immune cells into immune desert tumors. He has led multiple early-phase clinical trials of STING pathway agonists and has contributed to understanding the mechanisms by which these agents remodel the tumor microenvironment. His work on combination strategies pairing innate activation with checkpoint blockade has shaped the field.